Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology

The Biology and Diagnosis of KRS

At a Glance

Kufor-Rakeb syndrome is diagnosed by combining characteristic juvenile-onset parkinsonism and related signs with two pathogenic or likely pathogenic ATP13A2 variants, one inherited from each parent. MRI may show brain atrophy, but a lack of visible iron does not rule out the condition.

Understanding how Kufor-Rakeb syndrome (KRS) is diagnosed involves looking at the unique biological blueprint of the body and the specific tools doctors use to see inside the brain. Because KRS is so rare, the diagnostic process is often a process of elimination, ruling out more common conditions before confirming the genetic cause [1][2].

The Biology of ATP13A2

KRS is caused by mutations in a gene called ATP13A2, also known as the PARK9 locus [3]. This gene provides instructions for making a protein that lives in the lysosomes—the recycling centers of your cells [4].

When the ATP13A2 gene is mutated, these “recycling centers” cannot function correctly. While the precise disease mechanism remains under study, researchers propose this leads to several problems inside the brain cells:

  • Waste Buildup: The cells struggle to break down old proteins and damaged mitochondria (the cell’s power plants) [5][6].
  • Metal Imbalance: The protein is involved in transporting metals and polyamines. When it is missing or broken, metals like iron may accumulate inside the cells in some cases [7][8].
  • Cell Stress: This combination of waste buildup and metal accumulation eventually stresses the brain cells, particularly in areas responsible for movement and thinking, leading to the symptoms of KRS [9][10].

Genetic Inheritance

KRS is an autosomal recessive condition [11]. This means a person must inherit two pathogenic (disease-causing) copies of the ATP13A2 gene—one from their mother and one from their father—to have the syndrome [12]. If a person has only one changed copy, they are a “carrier” and typically do not show any symptoms of the disease [11].

The Diagnostic Process

Diagnosis usually begins with a clinical suspicion based on the presentation of juvenile-onset parkinsonism, cognitive decline, and psychiatric symptoms [13][14].

  1. Clinical Evaluation: A neurologist looks for specific signs like spasticity (muscle tightness), supranuclear gaze palsy (trouble moving the eyes upward), and minimyoclonus (small finger jerks) [13][15].
  2. Genetic Testing: Doctors may use a targeted “movement disorder panel” or whole exome sequencing to find mutations in the ATP13A2 gene [12][13]. A diagnosis generally requires a compatible clinical phenotype plus two pathogenic or likely pathogenic variants in the ATP13A2 gene; a single variant, or a variant of uncertain significance, does not establish KRS. Parental phase testing (to confirm one mutation came from each parent) and deletion/duplication analysis may be used when appropriate.
  3. Brain Imaging (MRI): An MRI is often performed to look for patterns of brain change. In many people with KRS, the MRI shows atrophy (shrinkage) of the cerebrum or cerebellum [16][17].

The Mystery of Iron on MRI

KRS is sometimes grouped with a family of diseases called NBIA (Neurodegeneration with Brain Iron Accumulation) because iron can sometimes build up in the brain cells [18][19]. However, unlike some other NBIA disorders, iron accumulation is inconsistent and iron buildup in KRS is not always visible on a standard MRI scan [7][9]. A “clean” MRI regarding iron does not rule out KRS, and iron-removing treatments are not a standard therapy [16][9].

Ruling Out Other Conditions

Because the symptoms of KRS can look like other diseases, doctors must perform a differential diagnosis to ensure they haven’t missed a different condition, especially those that might be treatable [1]:

  • Wilson Disease: A treatable condition where copper builds up in the body. Doctors rule this out with blood and urine tests for copper and a specialized eye exam [2].
  • Other Juvenile Parkinsonisms: Conditions caused by genes like PRKN or PINK1 usually cause movement problems but often lack the eye movement issues and early cognitive decline seen in KRS [20][13].
  • Other NBIA Disorders: Conditions like PLA2G6-associated neurodegeneration can look very similar to KRS, featuring both parkinsonism and cognitive decline, and are also diagnosed through genetic testing [21][19].
  • Hereditary Spastic Paraplegia (HSP): Some forms of HSP cause leg stiffness that can mimic the early stages of KRS [22][1].

By carefully comparing these possibilities, your medical team can confirm a diagnosis of Kufor-Rakeb syndrome and begin creating a management plan tailored to your specific needs.

Common questions in this guide

What causes Kufor-Rakeb syndrome?
Kufor-Rakeb syndrome is caused by disease-causing changes in both copies of the ATP13A2 gene, usually with one copy inherited from each parent. The gene helps make a protein involved in the cell’s recycling system, and its loss can place brain cells under stress.
What genetic result can confirm Kufor-Rakeb syndrome?
Doctors generally look for a compatible set of clinical signs plus two pathogenic or likely pathogenic variants in ATP13A2, with one variant on each copy of the gene. A single variant or a variant of uncertain significance does not by itself establish the diagnosis; parental testing can help clarify how the variants were inherited.
Can a normal MRI rule out Kufor-Rakeb syndrome?
No. MRI may show shrinkage of the cerebrum or cerebellum, but iron buildup is inconsistent and may not be visible on a standard scan. The absence of visible iron does not rule out Kufor-Rakeb syndrome.
Which tests help rule out Wilson disease when KRS is suspected?
Doctors may use blood and urine tests that measure copper and a specialized eye examination to evaluate for Wilson disease. This is important because Wilson disease can resemble KRS but has specific treatments.
What type of genetic testing is used for KRS?
Testing may include a movement-disorder gene panel or whole exome sequencing to look for ATP13A2 variants. Parental testing and deletion or duplication analysis may be added when the initial results do not fully explain the clinical findings.

Get notified when new evidence is published on Kufor-Rakeb syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Parkinsonian-Pyramidal syndromes: A systematic review.

    Tranchant C, Koob M, Anheim M

    Parkinsonism & related disorders 2017; (39()):4-16 doi:10.1016/j.parkreldis.2017.02.025.

    PMID: 28256436
  2. 2

    Clinical and neuroimaging phenotypes of genetic parkinsonism from infancy to adolescence.

    Morales-Briceño H, Mohammad SS, Post B, et al.

    Brain : a journal of neurology 2020; (143(3)):751-770 doi:10.1093/brain/awz345.

    PMID: 31800013
  3. 3

    The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.

    Park JS, Blair NF, Sue CM

    Movement disorders : official journal of the Movement Disorder Society 2015; (30(6)):770-9 doi:10.1002/mds.26243.

    PMID: 25900096
  4. 4

    ATP13A2 deficiency disrupts lysosomal polyamine export.

    van Veen S, Martin S, Van den Haute C, et al.

    Nature 2020; (578(7795)):419-424 doi:10.1038/s41586-020-1968-7.

    PMID: 31996848
  5. 5

    ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion.

    Wang R, Tan J, Chen T, et al.

    The Journal of cell biology 2019; (218(1)):267-284 doi:10.1083/jcb.201804165.

    PMID: 30538141
  6. 6

    Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.

    Anand N, Holcom A, Broussalian M, et al.

    Neurobiology of disease 2020; (139()):104786 doi:10.1016/j.nbd.2020.104786.

    PMID: 32032734
  7. 7

    Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay.

    Kırımtay K, Temizci B, Gültekin M, et al.

    Brain research 2021; (1750()):147167 doi:10.1016/j.brainres.2020.147167.

    PMID: 33091395
  8. 8

    Disruption of intracellular iron homeostasis through mitochondrial dysfunction associated with suppression of ATP 13A2 expression.

    Murakami T, Ohuchi K, Kiuchi M, et al.

    Scientific reports 2026; (16(1)):5007 doi:10.1038/s41598-026-35368-x.

    PMID: 41520027
  9. 9

    Clinical Evaluation of Three KRS Families and Cellular Analysis of Distinct ATP13A2 Mutations Reveal Different Levels of Iron Accumulation.

    Erterek E, Temizci B, Tekgül Ş, et al.

    Journal of neurochemistry 2026; (170(4)):e70418 doi:10.1111/jnc.70418.

    PMID: 41944191
  10. 10

    Overexpression of human Atp13a2Isoform-1 protein protects cells against manganese and starvation-induced toxicity.

    Ugolino J, Dziki KM, Kim A, et al.

    PloS one 2019; (14(8)):e0220849 doi:10.1371/journal.pone.0220849.

    PMID: 31393918
  11. 11

    Kufor-Rakeb syndrome-associated psychosis: a novel loss-of-function ATP13A2 variant and response to antipsychotic therapy.

    Colijn MA, Vrijsen S, Au PYB, et al.

    Neurogenetics 2024; (25(4)):405-415 doi:10.1007/s10048-024-00767-7.

    PMID: 39023817
  12. 12

    Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.

    Inzelberg R, Estrada-Cuzcano A, Laitman Y, et al.

    Journal of Parkinson's disease 2018; (8(3)):399-403 doi:10.3233/JPD-181360.

    PMID: 29966207
  13. 13

    Clinical and ultrastructural findings in an ataxic variant of Kufor-Rakeb syndrome.

    Pietrzak A, Badura-Stronka M, Kangas-Kontio T, et al.

    Folia neuropathologica 2019; (57(3)):285-294 doi:10.5114/fn.2019.88459.

    PMID: 31588715
  14. 14

    Psychiatric Manifestations of ATP13A2 Mutations.

    Balint B, Damasio J, Magrinelli F, et al.

    Movement disorders clinical practice 2020; (7(7)):838-841 doi:10.1002/mdc3.13034.

    PMID: 33033738
  15. 15

    Action Myoclonus and Seizure in Kufor-Rakeb Syndrome.

    Rohani M, Lang AE, Sina F, et al.

    Movement disorders clinical practice 2018; (5(2)):195-199 doi:10.1002/mdc3.12570.

    PMID: 30868101
  16. 16

    Kufor-Rakeb syndrome: a cohort-based clinical, imaging and genetic profile.

    Roy S, Mahale RR

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):106.

    PMID: 41493629
  17. 17

    Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.

    Park JS, Sue CM

    Current protein & peptide science 2017; (18(7)):725-732 doi:10.2174/1389203717666160311121534.

    PMID: 26965689
  18. 18

    Different cortical excitability profiles in hereditary brain iron and copper accumulation.

    Dubbioso R, Ruggiero L, Esposito M, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(3)):679-685 doi:10.1007/s10072-019-04147-0.

    PMID: 31773358
  19. 19

    Early-Onset Parkinsonism and Halo Sign: Beta-propeller Proteinassociated Neurodegeneration.

    Samanta D, Ramakrishnaiah R

    Journal of pediatric neurosciences 2020; (15(3)):325-327 doi:10.4103/jpn.JPN_62_20.

    PMID: 33531960
  20. 20

    The genetic landscape of Parkinson's disease.

    Lunati A, Lesage S, Brice A

    Revue neurologique 2018; (174(9)):628-643 doi:10.1016/j.neurol.2018.08.004.

    PMID: 30245141
  21. 21

    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.

    Magrinelli F, Mehta S, Di Lazzaro G, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(1)):148-161 doi:10.1002/mds.28807.

    PMID: 34622992
  22. 22

    Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

    Estrada-Cuzcano A, Martin S, Chamova T, et al.

    Brain : a journal of neurology 2017; (140(2)):287-305 doi:10.1093/brain/aww307.

    PMID: 28137957

This page explains Kufor-Rakeb syndrome biology and diagnosis for informational purposes only and does not constitute medical advice. A neurologist or genetics professional should interpret your symptoms, MRI, and ATP13A2 results in the context of your care.

Guide contents Kufor-Rakeb syndrome
Research & Literature
02 Symptoms and Disease Progression 04 Managing Symptoms and Treatment Options